80 FR 45663 - Findings of Research Misconduct
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Office of the Secretary Federal Register Volume 80, Issue 147 (July 31, 2015)
Office of the Secretary
Federal Register Volume 80, Issue 147 (July 31, 2015)
| Page Range | 45663-45664 | |
| FR Document | 2015-18756 |
[Federal Register Volume 80, Number 147 (Friday, July 31, 2015)] [Notices] [Pages 45663-45664] From the Federal Register Online [www.thefederalregister.org] [FR Doc No: 2015-18756] ----------------------------------------------------------------------- DEPARTMENT OF HEALTH AND HUMAN SERVICES Office of the Secretary Findings of Research Misconduct AGENCY: Office of the Secretary, HHS. ACTION: Notice. ----------------------------------------------------------------------- SUMMARY: Notice is hereby given that the Office of Research Integrity (ORI) has taken final action in the following case: Julie Mass[egrave], Pennsylvania State University (PSU): Based on an assessment conducted by the Pennsylvania State University College of Medicine (PSU-COM) and the Respondent's admission, ORI and PSU found that Ms. Julie Mass[egrave], former postdoctoral scholar, PSU-COM, engaged in research misconduct in research supported by National Cancer Institute (NCI), National Institutes of Health (NIH), grant 4 R00 CA138498. ORI found that the Respondent knowingly engaged in research misconduct by falsifying and/or fabricating Western blot data and analyses that were including in the following manuscript:``Cellular invasion following p120-catenin loss is mediated by AP-1, ITGA2 and MMP11,'' submitted to Molecular Cancer Research (hereafter referred to as the ``Molecular Cancer Research manuscript''). ORI found that the Respondent knowingly falsified and/or fabricated Western blot images, by manipulating the images to give the desired results, and quantitative PCR data and cell invasion and migration data, which were included in Figures 2, 3, S1, and S2 in the Molecular Cancer Research manuscript. Specifically, ORI found that the Respondent included falsified and/ or fabricated data and images in the following figures, and the corresponding text, in the Molecular Cancer Research manuscript: 1. Bands were cut and pasted from different Western blots for the following figures: a. Figures 2A, lanes 2 and 3, for P-cJun (S73) b. Figure 2D, lanes 4 and 6, bands identified as ITGA2 c. Figure 3B, bands identified as ITGA2 and MMP11 d. Figure 3D, bands identified as ITGA2 and MMP11 for lanes M2Neo- [uarr]ITGA2 control and [darr]MMP1 e. Figure 3E, bands identified as ITGA2 and MMP11 for lanes M2KO- [darr]ITGA2 control and M2KO-[darr]ITGA2-[uarr]MMP11 f. Figure S1A, bands identified as P-cJun (S73) g. Figure S2A, bands identified as P-cJun (S73) h. Figure S2C, bands identified as P-cJun (S73) i. Figure S2E, bands identified ITGA2 and MMP11 j. Figures S4B and C, identical bands were used for [beta]-actin 2. Numbers were increased or decreased in cell invasion and migration assays to give the desired results in the following figures: a. Figure 2B, for M2KO-DMSO cells and M2KO-SR11302 cells b. Figure 3F, for M2Neo-[uarr]ITGA2 [darr]MMP11 c. Figure 3G, for M2KO-[darr]ITGA2 [uarr]MMP11 d. Figure S1B, for F2KO-cJun peptide e. Figure S2B, for F2KO-cJun DMSO and F2KO-cJun SR11302 f. Figure S2D, for F2KO-cJun peptide g. Figure S2F, for F2Tom-[uarr]ITGA2 and F2KO-[darr]ITGA2 peptide h. Figures S4A, B, C, and D, for the migration for M2KO and F2KO cells 3. qPCR numbers were altered in Figure 2C, for M2KO-DMSO-PcJun ChIP and for M2KO-SR11302-PcJun ChIP, to give the desired result of PcJun binding to ITGA2 promoter. Ms. Mass[egrave] has entered into a Voluntary Settlement Agreement and has voluntarily agreed for a period of two (2) years, beginning on July 6, 2015: (1) To have her research supervised; Respondent agreed that prior to the submission of an application for U.S. Public Health Service (PHS) support for a research project on which her participation is proposed and prior to her participation in any capacity on PHS- supported research, Respondent shall ensure that a plan for supervision of her duties is submitted to ORI for approval; the supervision plan must be designed to ensure the scientific integrity of her research contribution; Respondent agreed that she will not participate in any PHS-supported research until such a supervision plan is submitted to and approved by ORI; Respondent agreed to maintain responsibility for compliance with the agreed upon supervision plan; (2) that any institution employing her shall submit in conjunction with each application for PHS funds, or report, manuscript, or abstract involving PHS-supported research in which Respondent is involved, a certification to ORI that the data provided by Respondent are based on actual [[Page 45664]] experiments or are otherwise legitimately derived, and that the data, procedures, and methodology are accurately reported in the application, report, manuscript, or abstract; and (3) to exclude herself voluntarily from serving in any advisory capacity to PHS including, but not limited to, service on any PHS advisory committee, board, and/or peer review committee, or as a consultant. FOR FURTHER INFORMATION CONTACT: Acting Director, Office of Research Integrity, 1101 Wootton Parkway, Suite 750, Rockville, MD 20852, (240) 453-8200. Donald Wright, Acting Director, Office of Research Integrity. [FR Doc. 2015-18756 Filed 7-30-15; 8:45 am] BILLING CODE 4150-31-P
![Federal Register / Vol. 80, No. 147 / Friday, July 31, 2015 / Notices 45663
TOTAL ESTIMATED ANNUALIZED BURDEN—HOURS—Continued
Average
Number
Number of burden per Total burden
Form name Type of respondent responses per
respondents response (hours)
respondent (hours)
Follow-Up Survey .............................. Health and Health Care Profes- 4208 1.00 10/60 701
sionals.
Follow-Up Survey .............................. Community Health Workers ............. 6 2.00 10/60 2
Focus Groups ................................... Health and Health Care Profes- 15 1.00 120/60 29
sionals.
Key Informant Interviews .................. Health and Health Care Profes- 13 1.00 60/60 13
sionals.
Key Informant Interviews .................. Community Health Workers ............. 25 1.00 60/60 25
Total ........................................... ........................................................... 23187 ........................ ........................ 2031
OS specifically requests comments on • ‘‘Cellular invasion following p120- a. Figure 2B, for M2KO-DMSO cells
(1) the necessity and utility of the catenin loss is mediated by AP-1, ITGA2 and M2KO-SR11302 cells
proposed information collection for the and MMP11,’’ submitted to Molecular b. Figure 3F, for M2Neo-↑ITGA2
proper performance of the agency’s Cancer Research (hereafter referred to as ↓MMP11
functions, (2) the accuracy of the the ‘‘Molecular Cancer Research c. Figure 3G, for M2KO-↓ITGA2
estimated burden, (3) ways to enhance manuscript’’). ↑MMP11
the quality, utility, and clarity of the ORI found that the Respondent d. Figure S1B, for F2KO-cJun peptide
information to be collected, and (4) the knowingly falsified and/or fabricated e. Figure S2B, for F2KO-cJun DMSO
use of automated collection techniques Western blot images, by manipulating and F2KO-cJun SR11302
or other forms of information the images to give the desired results, f. Figure S2D, for F2KO-cJun peptide
technology to minimize the information and quantitative PCR data and cell g. Figure S2F, for F2Tom-↑ITGA2 and
collection burden. invasion and migration data, which F2KO-↓ITGA2 peptide
were included in Figures 2, 3, S1, and h. Figures S4A, B, C, and D, for the
Darius Taylor, migration for M2KO and F2KO cells
S2 in the Molecular Cancer Research
Paperwork Reduction Act Clearance Officer. manuscript. 3. qPCR numbers were altered in
[FR Doc. 2015–18810 Filed 7–30–15; 8:45 am] Specifically, ORI found that the Figure 2C, for M2KO-DMSO-PcJun ChIP
BILLING CODE 4150–29–P Respondent included falsified and/or and for M2KO-SR11302-PcJun ChIP, to
fabricated data and images in the give the desired result of PcJun binding
following figures, and the corresponding to ITGA2 promoter.
DEPARTMENT OF HEALTH AND text, in the Molecular Cancer Research Ms. Massè has entered into a
HUMAN SERVICES manuscript: Voluntary Settlement Agreement and
1. Bands were cut and pasted from has voluntarily agreed for a period of
Office of the Secretary two (2) years, beginning on July 6, 2015:
different Western blots for the following
figures: (1) To have her research supervised;
Findings of Research Misconduct
a. Figures 2A, lanes 2 and 3, for P- Respondent agreed that prior to the
AGENCY: Office of the Secretary, HHS. cJun (S73) submission of an application for U.S.
b. Figure 2D, lanes 4 and 6, bands Public Health Service (PHS) support for
ACTION: Notice. a research project on which her
identified as ITGA2
c. Figure 3B, bands identified as participation is proposed and prior to
SUMMARY: Notice is hereby given that her participation in any capacity on
ITGA2 and MMP11
the Office of Research Integrity (ORI) PHS-supported research, Respondent
d. Figure 3D, bands identified as
has taken final action in the following shall ensure that a plan for supervision
ITGA2 and MMP11 for lanes M2Neo-
case:
↑ITGA2 control and ↓MMP1 of her duties is submitted to ORI for
Julie Massè, Pennsylvania State e. Figure 3E, bands identified as approval; the supervision plan must be
University (PSU): Based on an ITGA2 and MMP11 for lanes M2KO- designed to ensure the scientific
assessment conducted by the ↓ITGA2 control and M2KO-↓ITGA2- integrity of her research contribution;
Pennsylvania State University College of ↑MMP11 Respondent agreed that she will not
Medicine (PSU–COM) and the f. Figure S1A, bands identified as P- participate in any PHS-supported
Respondent’s admission, ORI and PSU cJun (S73) research until such a supervision plan is
found that Ms. Julie Massè, former g. Figure S2A, bands identified as P- submitted to and approved by ORI;
postdoctoral scholar, PSU–COM, cJun (S73) Respondent agreed to maintain
engaged in research misconduct in h. Figure S2C, bands identified as P- responsibility for compliance with the
research supported by National Cancer cJun (S73) agreed upon supervision plan;
asabaliauskas on DSK5VPTVN1PROD with NOTICES
Institute (NCI), National Institutes of i. Figure S2E, bands identified ITGA2 (2) that any institution employing her
Health (NIH), grant 4 R00 CA138498. and MMP11 shall submit in conjunction with each
ORI found that the Respondent j. Figures S4B and C, identical bands application for PHS funds, or report,
knowingly engaged in research were used for b-actin manuscript, or abstract involving PHS-
misconduct by falsifying and/or 2. Numbers were increased or supported research in which
fabricating Western blot data and decreased in cell invasion and migration Respondent is involved, a certification
analyses that were including in the assays to give the desired results in the to ORI that the data provided by
following manuscript: following figures: Respondent are based on actual
VerDate Sep<11>2014 17:44 Jul 30, 2015 Jkt 235001 PO 00000 Frm 00025 Fmt 4703 Sfmt 4703 E:\FR\FM\31JYN1.SGM 31JYN1](https://thefederalregister.org/doc/80_FR_45810/page/1.svg)
![45664 Federal Register / Vol. 80, No. 147 / Friday, July 31, 2015 / Notices
experiments or are otherwise Microbiology and Infectious Diseases Rockledge Dr., Suite 6185A, Bethesda,
legitimately derived, and that the data, Research, National Institutes of Health, HHS) MD 20892, or call non-toll-free number
procedures, and methodology are Dated: July 27, 2015. 301–435–1032, or Email your request,
accurately reported in the application, David Clary, including your address to
report, manuscript, or abstract; and Program Analyst, Office of Federal Advisory deshiree.belis@nih.gov. Formal requests
(3) to exclude herself voluntarily from Committee Policy. for additional plans and instruments
serving in any advisory capacity to PHS [FR Doc. 2015–18752 Filed 7–30–15; 8:45 am] must be requested in writing.
including, but not limited to, service on BILLING CODE 4140–01–P Proposed Collection: New Assessment
any PHS advisory committee, board, of NHLBI’s Global Health Initiative
and/or peer review committee, or as a Collaborating Centers of Excellence
consultant. DEPARTMENT OF HEALTH AND (NHLBI), 0925—New, National Heart,
FOR FURTHER INFORMATION CONTACT: HUMAN SERVICES Lung, and Blood Institute (NHLBI), the
Acting Director, Office of Research National Institutes of Health (NIH).
Integrity, 1101 Wootton Parkway, Suite National Institutes of Health Need and Use of Information
750, Rockville, MD 20852, (240) 453– Collection: This collection proposes to
Submission for OMB Review; 30-Day
8200. conduct a one-time outcome evaluation
Comment Request; New Assessment
of the NHLBI Global Health Initiative
Donald Wright, of NHLBI’s Global Health Initiative
Centers of Excellence (GHI COE)
Acting Director, Office of Research Integrity. Collaborating Centers of Excellence
Program to examine the extent to which
[FR Doc. 2015–18756 Filed 7–30–15; 8:45 am]
SUMMARY: Under the provisions of the program achieved its intended
BILLING CODE 4150–31–P Section 3507(a)(1)(D) of the Paperwork objectives in developing sustainable
Reduction Act of 1995, the National research and research training capacity,
Institutes of Health (NIH) has submitted and advancing information about the
DEPARTMENT OF HEALTH AND
to the Office of Management and Budget prevention and treatment of chronic
HUMAN SERVICES
(OMB) a request for review and non-communicable chronic
National Institutes of Health approval of the information collection cardiovascular and pulmonary diseases
listed below. This proposed information (CVPD) in low- and middle-income
National Institute of Allergy and collection was previously published in country (LMIC) populations. The
Infectious Diseases; Notice of Closed the Federal Register on 3/13/2015, outcome evaluation will utilize a mixed-
Meeting document number 2015–05722, pages methods approach to comprehend each
13396–13397. One comment was COE’s processes, short term outcomes,
Pursuant to section 10(d) of the received. The purpose of this notice is and sustainability outcomes/efforts.
Federal Advisory Committee Act, as to allow an additional 30 days for public Specifically, the evaluation will involve
amended (5 U.S.C. App.), notice is comment. The National Heart, Lung and triangulating quantitative data sources
hereby given of the following meeting. Blood Institute (NHLBI), National (e.g., archived systematic reporting
The meeting will be closed to the Institutes of Health, may not conduct or data), and qualitative data sources (e.g.,
public in accordance with the sponsor, and the respondent is not archival data and key informant
provisions set forth in sections required to respond to, an information interview data). Data collected will be
552b(c)(4) and 552b(c)(6), Title 5 U.S.C., collection that has been extended, used to develop a Case Study report for
as amended. The contract proposals and revised, or implemented on or after each COE outlining their experience
the discussions could disclose October 1, 1995, unless it displays a with implementing their program as
confidential trade secrets or commercial currently valid OMB control number. well as a comprehensive cross-site
property such as patentable material, Direct Comments to OMB: Written Lessons Learned Report describing
and personal information concerning comments and/or suggestions regarding knowledge and experiences from the
individuals associated with the contract the item(s) contained in this notice, overall program, including similarities
proposals, the disclosure of which especially regarding the estimated and differences across a variety of
would constitute a clearly unwarranted public burden and associated response project settings and conditions.
invasion of personal privacy. time, should be directed to the: Office Findings from interviews will be
Name of Committee: National Institute of of Management and Budget, Office of incorporated into the Case Studies
Allergy and Infectious Diseases Special Regulatory Affairs, OIRA_submission@ report and Lessons Learned report,
Emphasis Panel; NIAID Peer Review Meeting. omb.eop.gov or by fax to 202–395–6974, which will be used by CTRIS to inform
Date: August 24–25, 2015. Attention: NIH Desk Officer.
Time: 8:00 a.m. to 5:00 p.m.
NHLBI and NIH stakeholders about
Agenda: To review and evaluate contract DATES: Comment Due Date: Comments structural issues relevant to planning
proposals. regarding this information collection are both global and domestic biomedical
Place: Hilton Washington/Rockville, 1750 best assured of having their full effect if research and training programs with
Rockville Pike, Rockville, MD 20852. received within 30-days of the date of diverse operational conditions and
Contact Person: Susana, DVM, Ph.D. this publication. challenges. Additionally, COEs may
Mendez, Scientific Review Officer, Scientific utilize the Case Studies report as a
FOR FURTHER INFORMATION CONTACT: To
Review Program, Division of Extramural marketing tool to attract additional
Activities, Room 3G53B, National Institutes obtain a copy of the data collection
asabaliauskas on DSK5VPTVN1PROD with NOTICES
plans and instruments, submit funding and media coverage.
of Health, NIAID, 5601 Fishers Lane Dr. MSC
9823, Bethesda, MD 20892–9823, (240) 669– comments in writing, or request more OMB approval is requested for 3
5077, mendezs@niaid.nih.gov. information on the proposed project, years. There are no costs to respondents
(Catalogue of Federal Domestic Assistance contact: Ms. Deshiree Belis, National other than their time. The total
Program Nos. 93.855, Allergy, Immunology, Heart, Lung, and Blood Institute, estimated annualized burden hours are
and Transplantation Research; 93.856, National Institutes of Health, 6705 36.
VerDate Sep<11>2014 17:44 Jul 30, 2015 Jkt 235001 PO 00000 Frm 00026 Fmt 4703 Sfmt 4703 E:\FR\FM\31JYN1.SGM 31JYN1](https://thefederalregister.org/doc/80_FR_45810/page/2.svg)
Document Created: 2015-12-15 13:00:00
Document Modified: 2015-12-15 13:00:00
| Category | Regulatory Information | |
| Collection | Federal Register | |
| sudoc Class | AE 2.7: GS 4.107: AE 2.106: | |
| Publisher | Office of the Federal Register, National Archives and Records Administration | |
| Section | Notices | |
| Action | Notice. | |
| Contact | Acting Director, Office of Research Integrity, 1101 Wootton Parkway, Suite 750, Rockville, MD 20852, (240) 453-8200. | |
| FR Citation | 80 FR 45663 |
2025 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR